Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

ViroVet N.V.. (1/27/17). "Press Release: Dr George Gunn, Former CEO of Novartis Animal Health, Appointed as Chairman at ViroVet". Leuven.

Organisations Organisation ViroVet N.V.
  Organisation 2 Novartis Animal Health Division
  Group Eli Lilly (Group)
Products Product animal health
  Product 2 consulting, business
Persons Person Gunn, George (Stonehaven Consulting 201701 CEO + Founder before CEO Novartis Animal Health + UK Agri Ministry)
  Person 2 Blomsma, Erwin (ViroVet 201509– CEO + Co-Founder before Okapi Sciences NV 201401 CEO + Co-founder)

ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that Dr George Gunn joined its board of directors.

Dr Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis until early 2015. Before joining Novartis in 2003, he worked with the UK's Ministry of Agriculture, Fisheries and Food in the 1970s and 1980s and held various functions in the Animal Health Industry from head of Janssen Animal Health in the UK in 1996 up to president of Pharmacia Animal Health in the early 2000s. Dr George Gunn is also on the board of Nextvet, Phibro Animal Health, Diversigen and Nuritas. He received the Animal Pharm Lifetime Achievement Award earlier this week (

Dr Erwin Blomsma, co-founder and CEO of ViroVet: “I first met George in 2013 when I still worked at Okapi Sciences and entered into a license agreement with Novartis Animal Health. We were impressed with the dynamics of Novartis and have enjoyed the close collaboration with their team. When we started the preparations for ViroVet’s financing round, it was clear to us that the expertise and insight of George would be extremely valuable to the company as our products will potentially disrupt the animal health industry. We are honoured that George accepted to become our chairman.”

Dr George Gunn, founder and CEO of Stonehaven Consulting: “The vaccine technology platform ViroVet is developing together with the Leuven University has the potential to change how we design, produce and handle vaccines today and it is a pleasure for me to be able to witness and hopefully contribute to this story.”


Note for editors

About ViroVet

ViroVet is a biopharmaceutical company with a clear objective to develop innovative technologies to improve the health and value of livestock. The company is headquartered in Heverlee near Leuven, Belgium and continues to build on the livestock assets and know-how that it has accumulated since 2008 while adding new products, including vaccines, to the pipeline.

More information

Dr. Erwin Blomsma, CEO ViroVet NV – – Ambachtenlaan 1, 3001 Heverlee, Belgium
Tel: +32 16 299 728 Fax: +32 16 299 727 BE 0634.891.328 Web: Twitter: @ViroVet

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for ViroVet N.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px

» top